Entela Xoxi

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

Thomas Morel, Francis Arickx, Gustaf Befrits et al. · Orphanet Journal of Rare Diseases · 2013 · 123 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +14

Activation and inhibition of Candida rugosa and Bacillus-related lipases by saturated fatty acids, evaluated by a new colorimetric microassay

Cristian Ruiz, Serena Falcocchio, Entela Xoxi et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2004 · 57 citations

Life Sciences, Biochemistry, Microbiology +17

MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY

Simona Montilla, Entela Xoxi, Pierluigi Russo et al. · International Journal of Technology Assessment in Health Care · 2015 · 51 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacy Practice +17

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

Karen Facey, Jaime Espín, E. Kent et al. · PharmacoEconomics · 2021 · 47 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +12

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy

Entela Xoxi, Karen Facey, Americo Cicchetti · Frontiers in Pharmacology · 2021 · 45 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +16